Exact Mass: 379.1815
Exact Mass Matches: 379.1815
Found 493 metabolites which its exact mass value is equals to given mass value 379.1815,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Angoline
Angoline is a benzophenanthridine alkaloid. Angoline is a natural product found in Bocconia arborea, Zanthoxylum zanthoxyloides, and other organisms with data available. Angoline is a potent and selective IL6/STAT3 signaling pathway inhibitor with an IC50 of 11.56 μM. Angoline inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation[1].
Kasugamycin
An amino cyclitol glycoside that is isolated from Streptomyces kasugaensis and exhibits antibiotic and fungicidal properties. Kasugamycin is an amino cyclitol glycoside that is isolated from Streptomyces kasugaensis and exhibits antibiotic and fungicidal properties. It has a role as a bacterial metabolite, a protein synthesis inhibitor and an antifungal agrochemical. It is an amino cyclitol glycoside, an aminoglycoside antibiotic, a monosaccharide derivative, a carboxamidine and an antibiotic fungicide. Kasugamycin has been reported in Streptomyces celluloflavus and Streptomyces kasugaensis. Kasugamycin. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=6980-18-3 (retrieved 2024-12-11) (CAS RN: 6980-18-3). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
Fumitremorgin C
Fumitremorgin C is produced by Aspergillus fumigatus and Neosartorya fischeri. Production by Aspergillus fumigatus and Neosartorya fischeri Fumitremorgin C. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=118974-02-0 (retrieved 2024-08-26) (CAS RN: 118974-02-0). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
Celabenzine
A cyclic spermidine alkaloid that is 2-phenyl-1,5,9-triazacyclotridecan-4-one in which the amino hydrogen at position 9 has been replaced by a benzoyl group.
N-methyl-2,3,7,8-tetramethoxybenzophenanthridine-6(5H)-one
droperidol
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AD - Butyrophenone derivatives D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C323 - Butyrophenone D005765 - Gastrointestinal Agents > D000932 - Antiemetics CONFIDENCE standard compound; INTERNAL_ID 1207 INTERNAL_ID 1207; CONFIDENCE standard compound CONFIDENCE standard compound; EAWAG_UCHEM_ID 3679 Droperidol is a butyrophenone-type Dopamine-2 receptor antagonist.
Droperidol
A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593) D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AD - Butyrophenone derivatives D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C323 - Butyrophenone D005765 - Gastrointestinal Agents > D000932 - Antiemetics Droperidol is a butyrophenone-type Dopamine-2 receptor antagonist.
Donepezil
Donepezil, marketed under the trade name Aricept (Eisai), is a centrally acting reversible acetyl cholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimers disease where it is used to increase cortical acetylcholine. It has an oral bioavailability of 100\\% and easily crosses the blood-brain barrier. Because it has a half life of about 70 hours, it can be taken once a day. Initial dose is 5 mg per day, which can be increased to 10 mg per day after an adjustment period of at least 4 weeks. Donepezil is a centrally acting reversible acetyl cholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimers disease where it is used to increase cortical acetylcholine. It is well absorbed in the gut with an oral bioavailability of 100\\% and easily crosses the blood-brain barrier. Because it has a half life of about 70 hours, it can be taken once a day. Currently, there is no definitive proof that use of donepezil or other similar agents alters the course or progression of Alzheimers disease. However, 6-12 month controlled studies have shown modest benefits in cognition and/or behavior. Pilot studies have reported that donepezil therapy may potentially have effects on markers of disease progression, such as hippocampal volume. Therefore, many neurologists, psychiatrists, and primary care physicians use donepezil in patients with Alzheimers disease. In 2005, the UK National Institute for Clinical Excellence (NICE) withdrew its recommendation for use of the drug for mild-to-moderate AD, on the basis that there is no significant improvement in functional outcome; Currently, there is no definitive proof that use of donepezil or other similar agents alters the course or progression of Alzheimers disease. However, 6-12 month controlled studies have shown modest benefits in cognition and/or behavior. Pilot studies have reported that donepezil therapy may potentially have effects on markers of disease progression, such as hippocampal volume. Therefore, many neurologists, psychiatrists, and primary care physicians use donepezil in patients with Alzheimers disease. In 2005, the UK National Institute for Clinical Excellence (NICE) withdrew its recommendation for use of the drug for mild-to-moderate AD, on the basis that there is no significant improvement in functional outcome; of quality of life or of behavioral symptoms. However, NICE revised its guidelines to suggest that donepezil be used in moderate stage patients for whom the evidence is strongest. While the drug is currently indicated for mild to moderate Alzheimers, there is also evidence from 2 trials that it may be effective for moderate to severe disease. An example of this is a Karolinska Institute paper published in The Lancet in early 2006, which states that donepezil improves cognitive function even in patients with severe Alzheimers disease symptoms. of quality of life or of behavioral symptoms. However, NICE revised its guidelines to suggest that donepezil be used in moderate stage patients for whom the evidence is strongest. While the drug is currently indicated for mild to moderate Alzheimers, there is also evidence from 2 trials that it may be effective for moderate to severe disease. An example of this is a Karolinska Institute paper published in The Lancet in early 2006, which states that donepezil improves cognitive function even in patients with severe Alzheimers disease symptoms. D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors N - Nervous system > N06 - Psychoanaleptics > N06D - Anti-dementia drugs > N06DA - Anticholinesterases D002491 - Central Nervous System Agents > D018697 - Nootropic Agents C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor D004791 - Enzyme Inhibitors
2-(Arabinosylamino)-3-(glucosylamino)propanenitrile
2-(Arabinosylamino)-3-(glucosylamino)propanenitrile is found in pulses. 2-(Arabinosylamino)-3-(glucosylamino)propanenitrile is a constituent of the seeds of Lathyrus sativus (chickling pea). Constituent of the seeds of Lathyrus sativus (chickling pea). 2-(Arabinosylamino)-3-(glucosylamino)propanenitrile is found in pulses.
Thaumatin b, recombinant
Thaumatin b, recombinant is used as a food additive [EAFUS] ("EAFUS: Everything Added to Food in the United States. [http://www.eafus.com/]")
Desmethyl Erlotinib
4-Hydroxy-N-phenyl-3,5-bis(1-pyrrolidinylmethyl)benzamide
4-Isopropylphenserine
Dacinostat
Licofelone
D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D004791 - Enzyme Inhibitors > D016859 - Lipoxygenase Inhibitors D002491 - Central Nervous System Agents > D000700 - Analgesics C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor D000893 - Anti-Inflammatory Agents Licofelone (ML-3000) is a dual COX/5-lipoxygenase (5-LOX) inhibitor (IC50=0.21/0.18 μM, respectively) for the treatment of osteoarthritis. Licofelone exerts anti-inflammatory and anti-proliferative effects. Licofelone induces apoptosis, and decreases the production of proinflammatory leukotrienes and prostaglandins[1][2][3].
4H-1-Benzopyran-8-acetic acid, 4-oxo-2-phenyl-, 2-(diethylamino)ethyl ester
Merafloxacin
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic
Oxypertine
N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AE - Indole derivatives C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist
8H-Purin-8-one, 7-(2-butynyl)-7,9-dihydro-9-(6-methoxy-3-pyridinyl)-6-(1-piperazinyl)-
2-(4-(3-Ethynylanilino)-6-(2-methoxyethoxy)quinazolin-7-yl)oxyethanol
2-(4-(2-Methylpyridin-4-yl)phenyl)-N-(4-(pyridin-3-yl)phenyl)acetamide
Bocconoline
Bocconoline is a natural product found in Zanthoxylum asiaticum, Zanthoxylum simulans, and other organisms with data available.
12-Hydroxy-11-methoxy-N-acetylnor-C-fluorocurarimine
CP-401387
CONFIDENCE standard compound; INTERNAL_ID 733; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5359; ORIGINAL_PRECURSOR_SCAN_NO 5357 CONFIDENCE standard compound; INTERNAL_ID 733; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5369; ORIGINAL_PRECURSOR_SCAN_NO 5367 CONFIDENCE standard compound; INTERNAL_ID 733; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5321; ORIGINAL_PRECURSOR_SCAN_NO 5316 CONFIDENCE standard compound; INTERNAL_ID 733; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5361; ORIGINAL_PRECURSOR_SCAN_NO 5360 CONFIDENCE standard compound; INTERNAL_ID 733; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5360; ORIGINAL_PRECURSOR_SCAN_NO 5359 CONFIDENCE standard compound; INTERNAL_ID 733; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5358; ORIGINAL_PRECURSOR_SCAN_NO 5353 CONFIDENCE standard compound; INTERNAL_ID 733; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9878; ORIGINAL_PRECURSOR_SCAN_NO 9873 CONFIDENCE standard compound; INTERNAL_ID 733; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9917; ORIGINAL_PRECURSOR_SCAN_NO 9915 CONFIDENCE standard compound; INTERNAL_ID 733; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9936; ORIGINAL_PRECURSOR_SCAN_NO 9935 CONFIDENCE standard compound; INTERNAL_ID 733; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9980; ORIGINAL_PRECURSOR_SCAN_NO 9978 CONFIDENCE standard compound; INTERNAL_ID 733; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9987; ORIGINAL_PRECURSOR_SCAN_NO 9985 CONFIDENCE standard compound; INTERNAL_ID 733; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10000; ORIGINAL_PRECURSOR_SCAN_NO 9999
L-gamma-Glutamyl-S-4-(2-hydroxybutyl)-L-cysteinyl-glycine
This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 16HP2005 to the Mass Spectrometry Society of Japan.
L-gamma-Glutamyl-S-3-(1-hydroxybutyl)-L-cysteinyl-glycine
This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 16HP2005 to the Mass Spectrometry Society of Japan.
(3Z)-8a-methoxy-3-{[2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl]methylidene}hexahydropyrrolo[1,2-a]pyrazine-1,4-dione|brevianamide R
12-hydroxy-4-methyl-8,11,15-trioxo-19H-(13betaH)-4,8-seco-crotalanane-14beta-carboxylic acid lactone|14-carboxy-8,12-dihydroxy-4alpha-methyl-11,15-dioxo-(13betaH,14betaH)-14,19-dihydro-crotalananium betaine 12-lactone|Retusamin|retusamine
14-hydroxy-2,3,6-trimethoxy-9,11,12,13,13a,14-hexahydro-dibenzo(f,h)-pyrrolo(1,2-b)-isochinolin
3-ethoxy-5-ethyl-4,5-dihydro-1-methoxy-4-oxodibenz(cd,f)indol-2-carboxylic acid ethyl ester
bruceolline M
An indole alkaloid that is 1H-indole substituted by a 3-hydroxy-3-methyl-2-oxobutyl group at position 3 and a beta-D-glucopyranosyl group attached to the indolic nitrogen. It has been isolated from the ethanol extract of the stems of Brucea mollis.
1,2,4-Trimethoxy-12,13-dihydro-12-methyl[1,3]benzodioxolo[5,6-c]phenanthridine
(2R,6S,2S)-2-O-acetyllobeline|(2R,6S,2??S)-2??-O-acetyl lobeline|(S)-2-[(2R,6S)-6-(2-acetyloxy-2-phenylethyl)-1-methylpiperidin-2-yl]-1-phenylethanone|(S)-2-[(2S,6R)-1-methyl-6-(2-oxo-2-phenylethyl)piperidin-2-yl]-1-phenylethyl acetate|[(S)-2-[(2S,6R)-1-methyl-6-(2-oxo-2-phenylethyl)piperidin-2-yl]-1-phenylethyl acetate]
1,3,8-trihydroxy-2,7-bis-(3-methyl-but-2-enyl)-10H-acridin-9-one|Atalaphyllidin|Atalaphyllidine+|Atalaphyllin
4-desmethylisotylocrebrine|4-Hydroxy-3,6,7-trimethoxyphenanthroindolizidine
4-(9H-beta-carbolin-1-ylmethyl)-5-(1-hydroxy-ethyl)-6-oxo-1,4,5,6-tetrahydro-pyridine-3-carboxylic acid methyl ester|Hydroxylyalidin|Hydroxylyalidine
(+/-)-julandine|3-(4-Methoxy-phenyl-2-(3,4-dimethoxy-phenyl)-1,6,7,8,9,9a-hexahydro-4H-chinolizin|8-(3,4-dimethoxy-phenyl)-7-(4-methoxy-phenyl)-1,3,4,6,9,9a-hexahydro-2H-quinolizine|Julandin|julandine
Val-Tyr-Val
A tripeptide formed from L-valine, L-tyrosine and L-valine residues joined in sequence.
Licofelone
D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D004791 - Enzyme Inhibitors > D016859 - Lipoxygenase Inhibitors D002491 - Central Nervous System Agents > D000700 - Analgesics C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor D000893 - Anti-Inflammatory Agents Licofelone (ML-3000) is a dual COX/5-lipoxygenase (5-LOX) inhibitor (IC50=0.21/0.18 μM, respectively) for the treatment of osteoarthritis. Licofelone exerts anti-inflammatory and anti-proliferative effects. Licofelone induces apoptosis, and decreases the production of proinflammatory leukotrienes and prostaglandins[1][2][3].
(E)-1-(L-cysteinylglycin-S-yl)-N-hydroxy-omega-(methylsulfanyl)nonan-1-imine
1,3,5-trihydroxy-2,4-bis(3-methylbut-2-enyl)-10H-acridin-9-one
C22H25N3O3_9-Methoxy-12-(2-methyl-1-propen-1-yl)-1,2,3,5a,6,11,12,14a-octahydro-5H,14H-pyrrolo[1,2:4,5]pyrazino[1,2:1,6]pyrido[3,4-b]indole-5,14-dione
C24H17N3O2_(7Z)-7-Benzylidene-6-methyl-6,7-dihydroquinazolino[3,2-a][1,4]benzodiazepine-5,13-dione
donepezil
D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors N - Nervous system > N06 - Psychoanaleptics > N06D - Anti-dementia drugs > N06DA - Anticholinesterases D002491 - Central Nervous System Agents > D018697 - Nootropic Agents C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor D004791 - Enzyme Inhibitors Donepezil, marketed under the trade name Aricept (Eisai), is a centrally acting reversible acetyl cholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimers disease where it is used to increase cortical acetylcholine. It has an oral bioavailability of 100\\% and easily crosses the blood-brain barrier. Because it has a half life of about 70 hours, it can be taken once a day. Initial dose is 5 mg per day, which can be increased to 10 mg per day after an adjustment period of at least 4 weeks.; Donepezil is a centrally acting reversible acetyl cholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimers disease where it is used to increase cortical acetylcholine. It is well absorbed in the gut with an oral bioavailability of 100\\% and easily crosses the blood-brain barrier. Because it has a half life of about 70 hours, it can be taken once a day.; Currently, there is no definitive proof that use of donepezil or other similar agents alters the course or progression of Alzheimers disease. However, 6-12 month controlled studies have shown modest benefits in cognition and/or behavior. Pilot studies have reported that donepezil therapy may potentially have effects on markers of disease progression, such as hippocampal volume. Therefore, many neurologists, psychiatrists, and primary care physicians use donepezil in patients with Alzheimers disease. In 2005, the UK National Institute for Clinical Excellence (NICE) withdrew its recommendation for use of the drug for mild-to-moderate AD, on the basis that there is no significant improvement in functional outcome; Currently, there is no definitive proof that use of donepezil or other similar agents alters the course or progression of Alzheimers disease. However, 6-12 month controlled studies have shown modest benefits in cognition and/or behavior. Pilot studies have reported that donepezil therapy may potentially have effects on markers of disease progression, such as hippocampal volume. Therefore, many neurologists, psychiatrists, and primary care physicians use donepezil in patients with Alzheimers disease. In 2005, the UK National Institute for Clinical Excellence (NICE) withdrew its recommendation for use of the drug for mild-to-moderate AD, on the basis that there is no significant improvement in functional outcome; of quality of life or of behavioral symptoms. However, NICE revised its guidelines to suggest that donepezil be used in moderate stage patients for whom the evidence is strongest. While the drug is currently indicated for mild to moderate Alzheimers, there is also evidence from 2 trials that it may be effective for moderate to severe disease. An example of this is a Karolinska Institute paper published in The Lancet in early 2006, which states that donepezil improves cognitive function even in patients with severe Alzheimers disease symptoms.; of quality of life or of behavioral symptoms. However, NICE revised its guidelines to suggest that donepezil be used in moderate stage patients for whom the evidence is strongest. While the drug is currently indicated for mild to moderate Alzheimers, there is also evidence from 2 trials that it may be effective for moderate to severe disease. An example of this is a Karolinska Institute paper published in The Lancet in early 2006, which states that donepezil improves cognitive function even in patients with severe Alzheimers disease symptoms. [HMDB]
Fumitremorgin C
An organic heteropentacyclic compound that is a mycotoxic indole alkaloid produced by several fungi. A potent and specific inhibitor of the breast cancer resistance protein multidrug transporter.
2-(Arabinosylamino)-3-(glucosylamino)propanenitrile
3-Fluoro-4-cyanophenyl trans-4- (4-n-butylcyclohexyl)benzoate
N-[[(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-propan-2-ylamino]methyl]pyridine-3-carboxamide
N-[3-(dimethylamino)propyl]-2-methylprop-2-enamide,1-ethenylpyrrolidin-2-one,sulfuric acid
7-FLUORO-3,4-DIHYDRO-4-[(5-ISOQUINOLINYLOXY)ACETYL]-3,3-DIMETHYL-2(1H)-QUINOXALINONE
7-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-5H-[1,3]dioxolo[4,5-f]indole
TERT-BUTYL 5-((4-METHYLPIPERAZIN-1-YL)SULFONYL)-1H-INDOLE-1-CARBOXYLATE
Dibucaine hydrochloride
C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent
cobalt,fluoren-9-one,1,2,3,4,5-pentamethylcyclopentane
3,7-diphenyl-6-(pyridin-2-ylmethoxy)-[1,2,4]triazolo[4,3-b]pyridazine
(1S)-(S)-pinanediol 1-ammonium trifluoroacetate-3-methylbutane-1-boronate
Spiroxatrine
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists Spiroxatrine (R 5188) is a selective, dual antagonist of 5-HT1α and α2-adrenergic, with the Ki values of 3.94, 224000, 118.5 nM for 5-HT1α, 5-HT1β and 5-HT2, respectively. Spiroxatrine (R 5188) has a sedative effect[1][2][3][4].
Frovatriptan
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist Frovatriptan succinate hydrate ((R)-Frovatriptan succinate hydrate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate hydrate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate hydrate has the potential for migraine research[1][2].
5,11-Dihydro-1-(phenylmethyl)-spiro[6H-indolo[3,2-c]quinoline-6,4-piperidine]
(2R)-2-[[(9H-Fluoren-9-ylmethoxy)carbonyl]amino]-2-methyl-6-heptenoic acid
(E)-2-((TERT-BUTYLDIMETHYLSILYLOXY)METHYL)-FURO[3,2-B]PYRIDINE-6-CARBALDEHYDE OXIME
1H-Pyrrolo[2,3-b]pyridine-3-ethanamine, N,N-dimethyl-1-(2-naphthalenylsulfonyl)-
(3-[(ACRIDINE-9-CARBONYL)-AMINO]-PROPYL)-CARBAMIC ACID TERT-BUTYL ESTER
(2R,3R,4S,5S)-2-[6-(3-bicyclo[2.2.1]heptanylamino)purin-9-yl]-5-(chloromethyl)oxolane-3,4-diol
Tetrahydropapaverine hydrochloride
Tetrahydropapaverine hydrochloride is one of the Tetrahydroisoquinolines. Tetrahydropapaverine hydrochloride has neurotoxic effects on dopamine neurons[1][2].
6-((1-(3-FLUORO-5-(TRIFLUOROMETHYL)BENZYL)PIPERIDIN-4-YL)AMINO)PYRIDAZINE-3-CARBONITRILE
N-[2-(3,4-dimethoxyphenyl)ethyl]-1-(2,6-dimethylphenoxy)propan-2-amine,hydrochloride
4-(4-METHYL-5-(2-(TRIFLUOROMETHYL)PHENYL)-4H-1,2,4-TRIAZOL-3-YL)BICYCLO[2.2.2]OCTANE-1-CARBOXYLIC ACID
N-(2-hydroxy-1-methyl-2-phenylethyl)-N,7,7-trimethyl-2-oxobicyclo[2.2.1]heptane-1-methanesulphonamide
4-[(2-Butyl-4-chloro-5-hydroxymethyl-1H-imidazol-1-yl)methyl]-1,1-biphenyl-2-carbonitrile
3-[1-(9H-fluoren-9-ylmethoxycarbonyl)piperidin-4-yl]propanoic acid
(3S)-3-cyclopentyl-3-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
2-[4-[2-[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]vinyl]phenyl]benzoxazole
(aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate
dicyclohexylamine (S)-2-hydroxy-4-(methylselanyl)butanoate
2-(4-diphenylmethyl-1-piperazinyl)ethyl 3-aminocrotonate
1-[4-(4.4.5.5-tetramethyl-[1.3.2]dioxaborolan-2-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid methyl ester
4-{4-[BIS(4-FLUOROPHENYL)METHYL]PIPERAZIN-1-YL}PHENYLAMINE
Atevirdine
C471 - Enzyme Inhibitor > C1589 - Reverse Transcriptase Inhibitor > C97453 - Non-nucleoside Reverse Transcriptase Inhibitor D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D018894 - Reverse Transcriptase Inhibitors D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors C254 - Anti-Infective Agent > C281 - Antiviral Agent
1-(2-AMINO-PHENYL)-PIPERIDIN-3-CARBAMICACIDTERT-BUYTLESTER
Dacinostat
C471 - Enzyme Inhibitor > C1946 - Histone Deacetylase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
6-N-BUTYL-2-(3,4-DIMETHOXYPHENYL)-8-METHYLQUINOLINE-4-CARBOXYLIC ACID
n-[3-(n-Hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D061965 - Matrix Metalloproteinase Inhibitors
1-Piperazinepropanoic acid, 4-dibenz(b,f)(1,4)oxazepin-11-yl-alpha,alpha-dimethyl-
(6E)-2,5-diamino-6-[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-ylidene]hexanoic acid
8H-Purin-8-one, 7-(2-butynyl)-7,9-dihydro-9-(6-methoxy-3-pyridinyl)-6-(1-piperazinyl)-
N2,N2-dimethyl-6-[[[1-(1-naphthalenyl)-5-tetrazolyl]thio]methyl]-1,3,5-triazine-2,4-diamine
2-((trans-2-(4-(Benzyloxy)phenyl)cyclopropyl)amino)-1-(4-methylpiperazin-1-yl)ethanone
7-Hydroxy-3-(2-methoxyphenyl)-8-[(4-methyl-1-piperidinyl)methyl]-1-benzopyran-4-one
methyl 4-{3-[1-(3-nitro-2-pyridinyl)-4-piperidinyl]-1H-pyrazol-5-yl}phenyl ether
6-[2-amino-5-(4-methoxyphenoxy)-1H-pyrimidin-6-ylidene]-3-(2-methylprop-2-enoxy)-1-cyclohexa-2,4-dienone
2-[(4-Chlorophenyl)methyl]-6-phenyl-5-(1-piperidinyl)-3-pyridazinone
2-[(3-Chlorophenyl)methyl]-6-phenyl-5-(1-piperidinyl)-3-pyridazinone
5-Tert-butyl-3-(4-chlorophenyl)-7-(2-ethyl-1-imidazolyl)pyrazolo[1,5-a]pyrimidine
2-[[Cyclohexyl(oxo)methyl]amino]acetic acid (2-oxo-1,2-diphenylethyl) ester
3-{2-[(propan-2-yl)amino]acetamido}-N-[3-(trifluoromethyl)phenyl]benzamide
1-ethyl-N-(phenylmethyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
1-(5-Chloro-2-Methoxyphenyl)-3-{6-[2-(Dimethylamino)-1-Methylethoxy]pyrazin-2-Yl}urea
oxypertine
N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AE - Indole derivatives C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist
[1-Propylsulfonyl-4-[[2-(trifluoromethyl)phenyl]methyl]piperidin-4-yl]methanol
Thaumatin b, recombinant
Thaumatin b, recombinant is used as a food additive [EAFUS] ("EAFUS: Everything Added to Food in the United States. [http://www.eafus.com/]") D000074385 - Food Ingredients > D005503 - Food Additives D010592 - Pharmaceutic Aids > D005421 - Flavoring Agents
1-hydroxy-3-[(2E,4E,6E)-8-methyldeca-2,4,6-trienoyl]-5-(4-oxidophenyl)-2-oxopyridin-4-olate
3,3-Dimethyl-2-oxobutyric acid 5-(6-aminopurin-9-yl)-3,4-dihydroxytetrahydrofuran-2-ylmethyl ester
L-Tyr-3-[[(E)-4-Methoxy-4-oxo-2-butenoyl]amino]-L-Ala-OH
2-[[(2R)-2-amino-3-[(E)-N-hydroxy-C-(8-methylsulfanyloctyl)carbonimidoyl]sulfanylpropanoyl]amino]acetic acid
(S)-2-((S)-2-((S)-2-Amino-3-methylbutanamido)-3-(4-hydroxyphenyl)propanamido)-3-methylbutanoic acid
5-amino-2-(1-ethylpropyl)-6-[(Z)-(2-methylindol-3-ylidene)methyl]-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-one
1-Benzimidazolyl-[2-(4-methoxyphenyl)-4-quinolinyl]methanone
ethyl N-[(E)-[1-[3-(4-methylphenoxy)propyl]indol-3-yl]methylideneamino]carbamate
1-[4-(4-Phenoxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide
Phe-Val-Asp
A tripeptide composed of L-phenylalanine, L-valine, and L-aspartic acid joined by peptide linkages.
Tyr-FMDP
A dipeptide composed of 3-{[(2E)-4-methoxy-4-oxobut-2-enoyl]amino}alanine and L-tyrosine joined by peptide linkages.
N-[3-(3,4-dihydro-1H-isoquinolin-2-yl)propyl]-2-(3-oxo-1,4-benzoxazin-4-yl)acetamide
3-(2-furanyl)-N-[3-(2-furanyl)-4-methylpentyl]-4-phenylbutanamide
2-{[(2-butoxyquinolin-4-yl)carbonyl]amino}-N,N-diethylethanaminium chloride
2-[[2-(4-Methoxyphenyl)-6-methyl-1-benzopyran-4-ylidene]amino]-4-methylpentanoic acid
2-[[2-(3,4-dihydro-2H-quinolin-1-yl)-2-oxoethyl]thio]-3-ethyl-4-quinazolinone
2-Methyl-1-phenyl-5-benzimidazolecarboxylic acid [2-(3-methylbutan-2-ylamino)-2-oxoethyl] ester
1-(1,4-dioxan-2-yl)-N-[[3-(diphenylmethyl)-1,2,4-oxadiazol-5-yl]methyl]-N-methylmethanamine
1-(2,3-Dihydroindol-1-yl)-2-[(4-propyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)thio]ethanone
4-[(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)methyl]-7-ethyl-1-benzopyran-2-one
1-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)-3-(3-pyridinylmethyl)thiourea
N-[1-(3,4-dimethylphenyl)-4,5,6,7-tetrahydroindazol-4-yl]-5-(methoxymethyl)-2-furancarboxamide
(2S,3R,4R)-1-[2-(dimethylamino)-1-oxoethyl]-4-(hydroxymethyl)-3-[4-(2-methoxyphenyl)phenyl]-2-azetidinecarbonitrile
(2S,3S,4R)-1-[2-(dimethylamino)-1-oxoethyl]-4-(hydroxymethyl)-3-[4-(2-methoxyphenyl)phenyl]-2-azetidinecarbonitrile
(2R,3R,4S)-2-cyano-3-[4-(2-cyclohexylethynyl)phenyl]-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide
(2S,3R,4R)-2-cyano-3-[4-(1-cyclohexenyl)phenyl]-N-cyclopentyl-4-(hydroxymethyl)-1-azetidinecarboxamide
(2S,3S,4S)-2-cyano-3-[4-(1-cyclohexenyl)phenyl]-N-cyclopentyl-4-(hydroxymethyl)-1-azetidinecarboxamide
(2S,3S,4R)-2-cyano-3-[4-(2-cyclohexylethynyl)phenyl]-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide
N-[[(2R,3R,4S)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]-1-(pyridin-2-ylmethyl)azetidin-2-yl]methyl]propanamide
N-[[(2S,3S,4R)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]-1-(pyridin-2-ylmethyl)azetidin-2-yl]methyl]propanamide
(2S,3R,4S)-3-[4-(1-cyclohexenyl)phenyl]-1-(5-ethyl-2-thiazolyl)-4-(hydroxymethyl)-2-azetidinecarbonitrile
(2R,3S,4S)-3-[4-(1-cyclohexenyl)phenyl]-1-(5-ethyl-2-thiazolyl)-4-(hydroxymethyl)-2-azetidinecarbonitrile
(2R,3S,4R)-2-cyano-3-[4-(2-cyclohexylethynyl)phenyl]-4-(hydroxymethyl)-N-propan-2-ylazetidine-1-carboxamide
(2R,3R,4R)-1-[2-(dimethylamino)-1-oxoethyl]-4-(hydroxymethyl)-3-[4-(2-methoxyphenyl)phenyl]-2-azetidinecarbonitrile
(2R,3R,4S)-3-[4-(1-cyclohexenyl)phenyl]-1-(5-ethyl-2-thiazolyl)-4-(hydroxymethyl)-2-azetidinecarbonitrile
(2R,3R,4R)-3-[4-(1-cyclohexenyl)phenyl]-1-(5-ethyl-2-thiazolyl)-4-(hydroxymethyl)-2-azetidinecarbonitrile
(2S,3S,4S)-3-[4-(1-cyclohexenyl)phenyl]-1-(5-ethyl-2-thiazolyl)-4-(hydroxymethyl)-2-azetidinecarbonitrile
(2S,3R,4S)-2-cyano-3-[4-(2-cyclohexylethynyl)phenyl]-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide
(2S,3R,4R)-2-cyano-3-[4-(2-cyclohexylethynyl)phenyl]-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide
N-(cyclopropylmethyl)-2-[(2R,5R,6S)-5-[[(3-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]acetamide
N-(cyclopropylmethyl)-2-[(2S,5S,6S)-5-[[(3-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]acetamide
N-(cyclopropylmethyl)-2-[(2R,5S,6S)-5-[[(3-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]acetamide
(2R,3S,4R)-1-[2-(dimethylamino)-1-oxoethyl]-4-(hydroxymethyl)-3-[4-(2-methoxyphenyl)phenyl]-2-azetidinecarbonitrile
(2S,3S,4S)-1-[2-(dimethylamino)-1-oxoethyl]-4-(hydroxymethyl)-3-[4-(2-methoxyphenyl)phenyl]-2-azetidinecarbonitrile
(2S,3R,4R)-3-[4-(1-cyclohexenyl)phenyl]-1-(5-ethyl-2-thiazolyl)-4-(hydroxymethyl)-2-azetidinecarbonitrile
(2S,3S,4S)-2-cyano-3-[4-(2-cyclohexylethynyl)phenyl]-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide
N-[[(2S,3R,4S)-1-(cyclopentylmethyl)-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-4-pyridinecarboxamide
N-[[(2R,3S,4R)-1-(cyclopentylmethyl)-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-4-pyridinecarboxamide
N-[[(2S,3R,4R)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]-1-(pyridin-2-ylmethyl)azetidin-2-yl]methyl]propanamide
1-[(2S,3R,4S)-2-[(cyclobutylmethylamino)methyl]-4-(hydroxymethyl)-3-phenyl-1-azetidinyl]-2-(3-pyridinyl)ethanone
1-[(2R,3S,4R)-2-[(cyclobutylmethylamino)methyl]-4-(hydroxymethyl)-3-phenyl-1-azetidinyl]-2-(3-pyridinyl)ethanone
N-(cyclopropylmethyl)-2-[(2S,5R,6S)-5-[[(3-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]acetamide
N-(cyclopropylmethyl)-2-[(2R,5S,6R)-5-[[(3-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]acetamide
N-(cyclopropylmethyl)-2-[(2S,5S,6R)-5-[[(3-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]acetamide
N-(cyclopropylmethyl)-2-[(2R,5R,6R)-5-[[(3-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]acetamide
N-(cyclopropylmethyl)-2-[(2S,5R,6R)-5-[[(3-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]acetamide
(2R,3S,4S)-1-[2-(dimethylamino)-1-oxoethyl]-4-(hydroxymethyl)-3-[4-(2-methoxyphenyl)phenyl]-2-azetidinecarbonitrile
(2R,3S,4R)-3-[4-(1-cyclohexenyl)phenyl]-1-(5-ethyl-2-thiazolyl)-4-(hydroxymethyl)-2-azetidinecarbonitrile
(2R,3S,4S)-2-cyano-3-[4-(2-cyclohexylethynyl)phenyl]-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide
N-[[(2S,3S,4R)-1-(cyclopentylmethyl)-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-4-pyridinecarboxamide
N-[[(2R,3R,4S)-1-(cyclopentylmethyl)-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-4-pyridinecarboxamide
N-[[(2S,3R,4S)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]-1-(pyridin-2-ylmethyl)azetidin-2-yl]methyl]propanamide
N-[[(2R,3S,4S)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]-1-(pyridin-2-ylmethyl)azetidin-2-yl]methyl]propanamide
N-[[(2R,3S,4R)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]-1-(pyridin-2-ylmethyl)azetidin-2-yl]methyl]propanamide
1-[(2R,3R,4S)-2-[(cyclobutylmethylamino)methyl]-4-(hydroxymethyl)-3-phenyl-1-azetidinyl]-2-(3-pyridinyl)ethanone
1-[(2S,3S,4R)-2-[(cyclobutylmethylamino)methyl]-4-(hydroxymethyl)-3-phenyl-1-azetidinyl]-2-(3-pyridinyl)ethanone
1-[(2R,3R,4R)-2-[(cyclobutylmethylamino)methyl]-4-(hydroxymethyl)-3-phenyl-1-azetidinyl]-2-(3-pyridinyl)ethanone
3-(4-Benzyloxy-3-methoxystyryl)-5-pentyl-4,5-dihydroisoxazole
thaumatin
D000074385 - Food Ingredients > D005503 - Food Additives D010592 - Pharmaceutic Aids > D005421 - Flavoring Agents
Triphyopeltine
An isoquinoline alkaloid that is the biaryl resulting from substitution of the hydrogen at the 7-position of (1R,3R)-1,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-8-ol by a 1-hydroxy-6-(hydroxymethyl)-8-methoxynaphthalen-5-yl group. It is a naphthylisoquinoline alkaloid found in Triphyophyllum peltatum.
Thr-Pro-Tyr
A tripeptide composed of L-threonine, L-proline, and L-tyrosine joined by peptide linkages.
N(6)-dansyl-L-lysine
An L-lysine derivative with a dansyl group at the N(6)-position.
ML381
ML381 (VU0488130) is a highly selective, central nervous system penetrant mAChR M5 orthogonal antagonist (IC50 = 450 nM; Ki = 340 nM). ML381 is unstable in rat plasma and can be mainly used as a molecular probe for in vitro and electrophysiological studies[1][2].
ML417
ML417 is a selective and brain penetrant D3 dopamine receptor (D3R) agonist, with an EC50 of 38 nM. ML417 potently promotes D3R-mediated β-arrestin translocation, G protein mediated signaling, and pERK phosphorylation with minimal effects on other GPCR-mediated signaling. ML417 exhibits neuroprotection against toxin-induced neurodegeneration of dopaminergic neurons[1]. ML417 is a selective and brain penetrant D3 dopamine receptor (D3R) agonist, with an EC50 of 38 nM. ML417 potently promotes D3R-mediated β-arrestin translocation, G protein mediated signaling, and pERK phosphorylation with minimal effects on other GPCR-mediated signaling. ML417 exhibits neuroprotection against toxin-induced neurodegeneration of dopaminergic neurons[1].
